faCellitate
| Invested since | 2022 |
| Based in | Baden-Württemberg |
About the company
faCellitate develops patented polymeric surface coatings for plastic and glassware enabling 3-dimensional cell culture, amongst other uses. Initially, the technology was developed at the BASF research department for polymers. The company and team were formed at Chemovator during a nearly three year incubation period and spun-off end of 2021. During the period at Chemovator from BASF, the company turned the technology platform into a pipeline of high-tech applications and start building an international digital marketing platform.
faCellitate is also advancing its platform technology into other areas. Under the brand BIOINSTRUCT™, the company is applying its technology to modify polymer coated surfaces with peptides to create biospecific lab material surfaces for customers.
faCellitate has its offices in Mannheim in a startup incubator environment and its labs in Heidelberg.
Do you want to
know more about this company?
More startups from Life Sciences
heartbeat ONE provides a streamlined patient management tool for health care facilities of all sizes. It offers intelligent evaluations of diagnostics and treatment methods. It supports the preparation, documentation and …
SIRION BIOTECH produces genetically modified cells and is technology provider in the area of viral vector systems. The specialist in RNAi technology distributes more than 100 products and services. A …
iAtros is a digital heart clinic and a fully integrated platform, providing better medical care for patients with cardiovascular problems around the clock. Among other services, iATROS offers smart sensor …
The Trans-Duodenal Barrier developed by TDC is a patented endoscopic transduodenal bypass implant for combined diabetes/obesity therapy that atraumatically prevents nutrient absorption in the duodenum and delays gastric emptying. The …
Treatment of sustainable plaque in coronary arteries through our proprietary catheter based device.
PreComb Therapeutics AG is a privately held Swiss biotech company founded in 2018 by Jens M. Kelm, Peter Steiner and Olivier Mauti with the aim of developing technologies that bring …
Corimmun is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative peptide and biological drugs in indications with unmet medical needs. Exit since …
